TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17106751

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Short (3 h) infusion of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of ifosfamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Short (3 h) infusion of ifosfamide
Number of subjects: 12
Study: 14713402

Group type: EXPERIMENTAL
Intervention: Intermittent human parathyroid hormone (PTH) - teriparatide (recombinant human PTH 1‐34), self-administered daily injections.
Number of subjects: 0
Study: 11488370

Group type: EXPERIMENTAL
Intervention: Long-term antidepressant treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Mood-stabilizing agents alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Mood-stabilizing agents combined with antidepressants
Number of subjects: 7
Study: 10511413

Group type: EXPERIMENTAL
Intervention: Azithromycin (8.0 g total dose over 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2068440

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (5 mg/kg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/d)
Number of subjects: 38
Study: 6402075

Group type: EXPERIMENTAL
Intervention: Follow-up measurements (number of visits)
Number of subjects: 110
Study: 30898173

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture to Lianquan (CV 23) and Fengfu (GV 16) for 15 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham electro-acupuncture for 15 min
Number of subjects: 40
Study: 29628196

Group type: EXPERIMENTAL
Intervention: Standardized knee injection cocktail and oral acetaminophen (standard group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine periarticular injection and oral acetaminophen (LB group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized knee injection cocktail and intravenous (IV) acetaminophen (IVA group)
Number of subjects: 0
Study: 28273870

Group type: EXPERIMENTAL
Intervention: Fiber cookie (24 g fiber from distarch phosphate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control cookie (0.5 g fiber)
Number of subjects: 28
Study: 23336703

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 66

Group type: COMPARATOR
Intervention: Supervised exercise
Number of subjects: 66
Study: 21416234

Group type: EXPERIMENTAL
Intervention: Real-time withdrawal symptom data collection via palmtop computers for 4 weeks (2 weeks pre-quit and 2 weeks post-quit)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Real-time reports of craving and negative affect
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 1504
Study: 19112278

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (4 mmol/kg)
Number of subjects: 100
Study: 17309328

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0
Study: 15517671

Group type: EXPERIMENTAL
Intervention: Periurethral injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transurethral injection
Number of subjects: 40
Study: 11510636

Group type: EXPERIMENTAL
Intervention: Malek's surgical protocol (modified at HRCA), lip and soft palate repair at 5.5 months, hard palate repair at 20 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: HRCA surgical protocol, lip repair between 3 and 27 months (mean 9 months), palate repair between 12 and 44 months (mean 19 months)
Number of subjects: 75
Study: 10514756

Group type: EXPERIMENTAL
Intervention: Musical therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no musical therapy)
Number of subjects: 30
Study: 8056006

Group type: EXPERIMENTAL
Intervention: Heparin (100 U.kg‐1 intravenously bolus before thrombolytic treatment and additional intravenous heparin to raise partial thromboplastin time to 2-2.5 times normal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Heparin (Group 1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no heparin, Group 2)
Number of subjects: 38
Study: 2685187

Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 25
Study: 970730

Group type: EXPERIMENTAL
Intervention: Aerosol salbutamol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 21
Study: 29129482

Group type: EXPERIMENTAL
Intervention: Prolonged uninterrupted sitting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regularly interrupted sitting by brief activity-breaks
Number of subjects: 0
Study: 28681366

Group type: EXPERIMENTAL
Intervention: Modified Jaw Opening Exercise (MJOE): one set of five repetitions at 80% maximum voluntary contraction (MVC) for 6 seconds, performed four sets a day, five times a week, for six weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isometric jaw closing exercise (Control): one set of five repetitions at 20% MVC for 6 seconds, performed four sets a day, five times a week, for six weeks
Number of subjects: 16
Study: 25891021

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA amplitude, 20 min daily for 5 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (active and sham tDCS)
Number of subjects: 32
Study: 23624136

Group type: EXPERIMENTAL
Intervention: distracting mini-meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 21455728

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 20
Study: 17855151

Group type: EXPERIMENTAL
Intervention: High-skill boys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased play area for boys
Number of subjects: 0

Group type: COMPARATOR
Intervention: Girls
Number of subjects: 0
Study: 16507605

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1,000 IU/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise (downhill running for 45 min at 75% maximal oxygen consumption)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise-induced responses
Number of subjects: 32
Study: 12601267

Group type: COMPARATOR
Intervention: General exercise training (GET)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: General exercise training (GET) and additional eccentric exercise training (EET)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eccentric exercise training (EET)
Number of subjects: 24
Study: 11137262

Group type: EXPERIMENTAL
Intervention: Meningococcal group C/CRM (197) conjugate vaccine (3 doses at 2, 3, and 4 months)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (3 doses)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Meningococcal group C/CRM (197) conjugate vaccine
Number of subjects: 248
Study: 9087155

Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (excluding those reported by the patient as responsible for previous reactions)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pyrazole derivatives (most common nonsteroidal antiinflammatory drugs involved)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7683800

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 3300120

Group type: EXPERIMENTAL
Intervention: Metronidazole-fosfomycin (M-F)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Metronidazole-gentamicin (M-G)
Number of subjects: 381
Study: 28703951

Group type: EXPERIMENTAL
Intervention: Escitalopram (n = 102)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo (n = 96)
Number of subjects: 353
Study: 26932256

Group type: EXPERIMENTAL
Intervention: Tissue tolerable plasma (TTP) administered six times each 7 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (nystatin, chlorhexidine and placebo treatment)
Number of subjects: 8
Study: 26573041

Group type: EXPERIMENTAL
Intervention: GnRH Agonist Microdose Flareup (MF)
Number of subjects: 123

Group type: COMPARATOR
Intervention: GnRH Antagonist/Letrozole (AL)
Number of subjects: 123
Study: 23840403

Group type: EXPERIMENTAL
Intervention: HAART and TB treatment
Number of subjects: 0
Study: 22024700

Group type: EXPERIMENTAL
Intervention: 500 mg oral levofloxacin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 500 mg oral ciprofloxacin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 250 mg levofloxacin and 250 mg ciprofloxacin co-administered
Number of subjects: 15
Study: 18780198

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 21:00 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 17:00 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 10:30 h
Number of subjects: 90
Study: 16493496

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g daily)
Number of subjects: 300

Group type: COMPARATOR
Intervention: corn oil (4 g daily)
Number of subjects: 300
Study: 12867313

Group type: EXPERIMENTAL
Intervention: 1-l volume air pocket
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-l volume air pocket
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall tests
Number of subjects: 12
Study: 10606835

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 12
Study: 9107154

Group type: EXPERIMENTAL
Intervention: Meta-chlorophenylpiperazine (m-CPP) infusion (0.08 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Light treatment
Number of subjects: 32
Study: 8219179

Group type: EXPERIMENTAL
Intervention: Intensified worker motivation through special regular sessions and closer supervision
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Usual procedures
Number of subjects: 1300
Study: 3902199

Group type: EXPERIMENTAL
Intervention: Cisplatin (CACP) + 5-fluorouracil (5-FU) infusion (CACP 100 mg/m2 day 1 and 5-FU 1000 mg/m2 24-hour infusion days 1-4)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cisplatin (CACP) + 5-fluorouracil (5-FU) bolus (CACP 100 mg/m2 day 1 and 5-FU 600 mg/m2 day 1 and day 8)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cisplatin + 5-FU bolus
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cisplatin + 5-FU infusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Complete responders on either arm
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Partial responders on either arm
Number of subjects: 44
Study: 30049256

Group type: EXPERIMENTAL
Intervention: Multiplex bead array (MBA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lateral flow assay (LFA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All three tests (MBA, ELISA, LFA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: At least one test (MBA, ELISA, LFA)
Number of subjects: 118
Study: 26684046

Group type: EXPERIMENTAL
Intervention: FS-LASIK
Number of subjects: 197

Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 197
Study: 24866923

Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP) provided to PCPs
Number of subjects: 266

Group type: COMPARATOR
Intervention: Usual care (no SCP provided)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: SCP provided to PCPs
Number of subjects: 266
Study: 24025632

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α-tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cured meat (nonsupplemented)
Number of subjects: 0
Study: 21037028

Group type: EXPERIMENTAL
Intervention: Operative treatment with accelerated functional rehabilitation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Nonoperative treatment with accelerated functional rehabilitation
Number of subjects: 144
Study: 19134433

Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil (VCO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 26
Study: 16178832

Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Case-based group discussion (CBGD)
Number of subjects: 83
Study: 12505552

Group type: EXPERIMENTAL
Intervention: Psychological treatment for insomnia
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no psychological treatment)
Number of subjects: 209
Study: 10211848

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise (running at 65-70% of VO2max to exhaustion)
Number of subjects: 10
Study: 8874330

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 145

Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 145
Study: 1781796

Group type: EXPERIMENTAL
Intervention: Memantine (1‐amino‐3,5‐dimethyl‐adamantane hydrochloride)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 548558

Group type: EXPERIMENTAL
Intervention: PGF2 alpha gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: PGE2 tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31023383

Group type: EXPERIMENTAL
Intervention: Written information sheets provided to proxies
Number of subjects: 30
Study: 28265144

Group type: EXPERIMENTAL
Intervention: Graston Technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static Stretching
Number of subjects: 24
Study: 25757503

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 20
Study: 23670880

Group type: EXPERIMENTAL
Intervention: Isolation of arrhythmogenic pulmonary veins (aPV) in AG group (n=105)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Isolation of all pulmonary veins (VG group, n=102)
Number of subjects: 207
Study: 21383110

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low MPH dose
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High MPH dose
Number of subjects: 56
Study: 19823178

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks in group I (ED)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 6 weeks in group II (no ED)
Number of subjects: 53
Study: 17076775

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flap Surgery
Number of subjects: 30
Study: 15505185

Group type: EXPERIMENTAL
Intervention: High-frequency left dorsolateral prefrontal rTMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study: 11504824

Group type: EXPERIMENTAL
Intervention: Thalidomide, 200 mg daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9011704

Group type: EXPERIMENTAL
Intervention: Warm bypass (37 degrees C, hematocrit 23%, pump flow 150 ml/kg per minute)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypothermic bypass (22 degrees C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypothermic low-flow bypass (75 ml/kg per minute)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypothermic low-hematocrit bypass (hematocrit 16%)
Number of subjects: 40
Study: 8215281

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg orally)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg intramuscularly)
Number of subjects: 181
Study: 2894217

Group type: EXPERIMENTAL
Intervention: ICI 118551 (150 mg daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29680317

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27237130

Group type: EXPERIMENTAL
Intervention: DNACPR
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: UFTO
Number of subjects: 231

Group type: COMPARATOR
Intervention: No-form
Number of subjects: 231
Study: 25167224

Group type: EXPERIMENTAL
Intervention: Exposure to information about overdiagnosis in breast cancer screening
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: Information format providing an estimate of the rate of overdiagnosis (simple ratio format)
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: General information on overdiagnosis
Number of subjects: 2272
Study: 24332065

Group type: EXPERIMENTAL
Intervention: Serum proteomics analysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Collagen I expression
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Serum levels of collagen I degradation telopeptide (CTx)
Number of subjects: 3
Study: 20584877

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg x 1 x IV + 90 mg x 1 x day V-VII
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tramadol sustained-release 100 mg x 2 x VII
Number of subjects: 100
Study: 18835335

Group type: EXPERIMENTAL
Intervention: Genuine irradiation from a 3G mobile phone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 29
Study: 16401321

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 249
Study: 12878617

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 40

Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 40
Study: 10394873

Group type: EXPERIMENTAL
Intervention: 1200 mg of ferric ammonium citrate
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 2400 mg of ferric ammonium citrate
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study: 9116394

Group type: EXPERIMENTAL
Intervention: Oral pamidronate (300 mg/day for 4 weeks every 4 months)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oral pamidronate (150 mg/day for 4 weeks every 2 months)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 1519713

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 6657002

Group type: EXPERIMENTAL
Intervention: Nomifensine (200 mg orally)
Number of subjects: 36
Study: 31688645

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20
Study: 31481366

Group type: EXPERIMENTAL
Intervention: CYPHP Evelina London model of care
Number of subjects: 2138

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2138
Study: 28125735

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback training (4 weekly sessions, 60-min each)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no neurofeedback)
Number of subjects: 13
Study: 25838513

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23429593

Group type: EXPERIMENTAL
Intervention: 6 mg/kg aflibercept, 1-hour intravenous
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 21055873

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy (RF group; n=19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 38
Study: 19707148

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 70

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 70
Study: 16552196

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aboral pouch (AP) construction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aboral pouch with preserved duodenal passage (APwPDP) reconstruction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 14505296

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/d)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Sertraline (147 mg)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 395
Study: 10381787

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day meloxicam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15 mg/day meloxicam
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9025799

Group type: EXPERIMENTAL
Intervention: M40 mask
Number of subjects: 9
Study: 10149615

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stems at 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated stems at 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated stems at 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated stems at 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (hydroxyapatite and uncoated)
Number of subjects: 60
Study: 6296755

Group type: EXPERIMENTAL
Intervention: Whole cell pertussis antigen with aluminum phosphate adjuvant (WcPh)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled whole cell groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled whole cell antigen group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual vaccines
Number of subjects: 0
Study: 30913161

Group type: EXPERIMENTAL
Intervention: Incongruent Stroop task (high cognitive load)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Congruent Stroop task (low cognitive load)
Number of subjects: 13
Study: 28375032

Group type: EXPERIMENTAL
Intervention: Test formulation of dalteparin sodium (DS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of dalteparin sodium (DS)
Number of subjects: 24
Study: 27323934

Group type: EXPERIMENTAL
Intervention: Progressive exercise and structured advice
Number of subjects: 33

Group type: COMPARATOR
Intervention: Structured advice only
Number of subjects: 33